key: cord-0845661-08q10gyi
authors: Farag, Youssef MK.
title: Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
date: 2020-10-01
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.09.033
sha: 8195251a4db3e90ae0ad27453ee877ab5e1f92ab
doc_id: 845661
cord_uid: 08q10gyi

nan

Joyner et al 1 reported safety update on the use of convalescent plasma transfusion in a convenience sample of 20,000 hospitalized COVID-19 patients. The authors should be applauded for undertaking this monumental effort in providing the medical community with this valuable data in a timely manner amid the pandemic. Upon reflecting on the methods and results, I would like to express reservation on some of the methods used and how the findings were interpreted.

First, table 1 offers important insights on the significant variability in the temporal trends of key variables. For example, proportion of patients who had "current severe or life-threatening COVID-19" decreased by ~22% from April to June 2020. The proportion of patients who had "high risk of severe or life-threatening COVID-19" increased by ~85% in the same time interval.

This may lead us to conclude that pooling the mortality proportion without stratifying by calendar month may not have been appropriate. This is also evident from figure 2 which shows that the mortality decreased by nearly 70% from week 1 to week 7.

Second, it seems that the reported cumulative incidence proportion of mortality is crude and was not adjusted for potential confounders. This is probably the most serious flaw in the analysis and interpretation of this data. Some of these confounders include age groups, sex, comorbidities (cardiovascular disease, hypertension, diabetes, chronic kidney disease, lung disease), laboratory data (hematology, liver and renal function), clinical status, clinical symptoms, time since hospitalization and calendar month (as described earlier). Furthermore, this data was collected from all over the US where lockdown measures and stay-at-home orders varied significantly during that time interval. Such variables should have been considered as potential confounders. In addition, numerous empirical medical practices were, and many are, practiced, e.g. the use of hydroxychloroquine, or experimental drugs, e.g. remdesivir. Such data J o u r n a l P r e -p r o o f was not collected/reported in this study which makes it impossible for the authors to decisively attribute, or not, whatever they observe to convalescent plasma.

Third, given the purely descriptive nature of this study, this is a large case series, with no comparison group, it is not appropriate to make any inferential statements. This includes the authors' strong statements on no increased risk of adverse cardiac or thrombotic/thromboembolic events or low mortality. With group of hospitalized COVID-19 patients who were not exposed to convalescent plasma transfusion, the authors may have been able to test a safety profile benefit, or lack thereof.

Fourth, the explanation to the declining mortality rate over the study period can also be confounded, positively or negatively, by other variables, including the decreasing mean age of COVID-19 patients 2 who have been shown to have a substantially lower risk of mortality 3 .

While it is true from their data that there were more critically-ill patients later in the study than earlier, there was also higher proportion of patients who are at higher risk of severe of lifethreatening COVID-19, as we described earlier. Attributing the decline in mortality to the "expeditious" availability of convalescent plasma is invalid and may not be relevant to the study findings, once again, given the absence of a comparison group.

Fifth, time since first symptom, hospitalization, ICU admission and mechanical ventilation to convalescent plasma transfusion should have been reported to take into account their potential impact on the timing of transfusion on mortality 4, 5 .

Sixth, the authors state that [this study] "…support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality". No data is provided to directly or indirectly support this. No comparison group, no temporal data on the natural progression of the disease in relation to convalescent plasma transfusion, no statistical adjustment for potential confounders and no adjusted subgroup or sensitivity analyses.

Finally, we believe that comparing these 20,000 patients to a group of patients who did not receive convalescent plasma transfusion would significantly contribute to the body of evidence J o u r n a l P r e -p r o o f in this area, not only in terms of safety but also effectiveness to reduce mortality, or even better, a randomized controlled trial to asses efficacy to reduce mortality.

Youssef MK Farag, MD, PhD, MPH Akebia Therapeutics, Inc., Cambridge, Massachusetts Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

Transcript for the CDC Telebriefing Update on COVID-19 Press Briefing Transcript Thursday

The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study